Loading...
Market
Will Gilead announce additional voluntary licensing agreements for lenacapavir by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases from Gilead Sciences
Story
Gilead Signs Royalty-Free Deals with Six Generics for Investigational HIV Drug Lenacapavir in 120 Countries
Oct 2, 2024, 01:35 PM
Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, including Dr. Reddy's Laboratories and Hetero, to enable access to its investigational HIV prevention medication, lenacapavir, across 120 high-incidence, resource-limited countries. Lenacapavir, pending regulatory approval, is a twice-yearly injectable drug used for HIV-1 prevention and treatment in heavily treatment-experienced adults. The agreements aim to increase global access to this groundbreaking medication, accelerating the global HIV response.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Mylan • 25%
Other • 25%